Investing.com - Needham downgraded Biogen Inc (NASDAQ: BIIB) on Monday, citing slower-than-expected growth for its ...
Needham has downgraded Biogen (BIIB) to hold from buy, citing a lack of near-term catalysts and slow uptake for the company’s ...
Needham downgraded Biogen Inc (NASDAQ:BIIB), citing limited catalysts for the company over the next year. Alzheimer’s drug ...
Worldcrunch on MSN16h
Leqembi, Is This New Drug The Turning Point In Curing Alzheimer’s?That Thursday, for the first time, the European Medicines Agency (EMA) approved a drug that targets the cause — not just the ...
GlobalData on MSN21h
How decentralisation can fill the gaps in Alzheimer’s researchAlzheimer’s trials face the unique challenge of studying participants with cognitive decline, amid a move towards digital ...
And this corruption even extends into the Food and Drug Administration (FDA). Three years ago, Biogen got the FDA to approve its Alzheimer drug Aduhelm, even though there was little proof of its ...
Baler, Aurora, Philippines Video Recording Date/Time: November 17, 2024 at 15:35h Super Typhoon Man-Yi, known locally as Pepito, made its second landfall in Dipaculao, Aurora, at 3:20 p.m. on Sunday, ...
(RTTNews) - UCB and Biogen Inc. (BIIB) presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol, a Fc-free anti-CD40L drug candidate, showing significant clinical ...
Alzheimer's disease—the most common form of dementia—is a progressive neurological disorder that causes brain cells to ...
Needham analyst Ami Fadia downgraded Biogen (BIIB) to Hold from Buy.Don't Miss our Black Friday Offers:Discover the latest stocks recommended ...
Enphase Energy Inc. $61.84 2.32 3.90% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback